LeadingAge NY Seeks Member Input on Monoclonal Antibody Therapy Interest
As you may know, there are two forms of monoclonal antibody (mAb) therapies available presently: an hour-long IV infusion and a series of four Subcutaneous (SQ) injections (each injection given in a separate location). Strict criteria exist for inclusion and exclusion based on the Emergency Use Authorization (EUA) documents issued by the Food and Drug Administration (FDA). These EUA documents, linked below, must be followed explicitly, as these medications are not FDA-approved.
Post-exposure prophylaxis (prevention) for residents has also been granted EUA and is in practice in some long term care facilities using the same medications.
LeadingAge NY is inquiring from members if there is further interest in or questions about mAb therapy, and if so, we will put together a presentation at a future date detailing the specifics of patient/resident monitoring, equipment specifics, emergency measures, and more.
The EUA documents are linked below for your reference:
- Imdevimab/Casirivimab (REGEN-COV) EUA document; more references on FDA website
- Bamlanivimab/Etesevimab EUA document and fact sheet for health care providers
Please email Mark Kepner-Clough with your interest in a future program on this topic by Oct. 22, 2021.
Contact: Mark Kepner-Clough, email@example.com, 518-867-8383 ext. 125